Cyprus clears company to supply cannabinoids for medical use

Cyprus has cleared a North American-based company who specializes in medical cannabis research and production, for distribution of cannabinoid formulations for patients in Cyprus, announced the company on Thursday.


The company, Tilray, which produces and distributes medical cannabis around the world, in an announcement on BusinessWire, said its cannabinoid products have been cleared for distribution in Cyprus after it had received necessary approvals in Canada and Cyprus.

“We are proud to be able to offer patients access to high-quality, pharmaceutical-grade medical cannabis products in Cyprus,” chairman Brendan Kennedy said.

The company also said it is working with Cyprus’ health ministry “to import and distribute Tilray Drops, a medical cannabis extract product, at pharmacies and healthcare facilities throughout the Mediterranean island to patients with advanced cases of cancer who have authorization to access medical cannabis products”.

The company describes itself as a global leader in medical cannabis research and production dedicated to advancing the science, safety, and efficacy of medical cannabis and cannabinoids.

It dded that it operates “one of the largest and most sophisticated federally licensed medical cannabis cultivation facilities in the world, offering a range of products to patients, physicians, pharmacies, governments, hospitals and researchers in Australia, Canada, the European Union and Latin America”.
 

Cyprus Mail